On November 11, 2021 Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, reported that Company’s Management will provide a corporate update and participate in one-on-one investor meetings at the Jefferies London Healthcare Conference, to be held virtually November 18-19, 2021 (Press release, Selecta Biosciences, NOV 11, 2021, View Source [SID1234595253]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details on the conference can be found below.
Jefferies Virtual London Healthcare Conference
Format: Presentation and one-on-one investor meetings
Date: Thursday November 18, 2021
Presentation Time: 8:00 a.m. GMT / 3:00 a.m. EST
Webcast: Click Here
An archived webcast will also be accessible in the Investors & Media section of the company’s website at www.selectabio.com.